In patients with advanced prostate cancer, it is important to determine whether and, if so, how long the chosen therapy will continue to work. Hormone therapies with abiraterone or enzalutamide often lose their effect after some time, with the tumor releasing a certain substance into the blood.
This is where the prostate monitor (AR/V7) comes into play. It allows us to test affected patients to see if this substance is detectable and whether the therapy needs to be adjusted accordingly! All we need is a blood sample.